Search
Search Results
-
Anti-CD38 antibody therapy for patients with relapsed/refractory multiple myeloma: differential mechanisms of action and recent clinical trial outcomes
CD38 is a transmembrane glycoprotein that functions both as a receptor and an ectoenzyme, playing key roles in the regulation of calcium signaling...
-
Hepatitis B reactivation in patients with multiple myeloma treated with anti-CD38 monoclonal antibody-based therapies: a pharmacovigilance analysis
BackgroundDaratumumab and isatuximab are anti-CD38 monoclonal antibodies indicated for the treatment of multiple myeloma. These agents can increase...
-
Real world data on outcomes of anti-CD38 antibody treated, including triple class refractory, patients with multiple myeloma: a multi-institutional report from the Canadian Myeloma Research Group (CMRG) Database
Multiple myeloma (MM) remains incurable despite the availability of novel agents. This multi-center retrospective cohort study used the Canadian...
-
Safety of Subcutaneous Daratumumab in Anti-CD38 Monoclonal Antibody-Naïve Patients with Plasma Cell Disorders: A Multicenter Real-Life Experience
BackgroundDaratumumab, an anti-CD38 monoclonal antibody, is used for treatment of multiple myeloma (MM) and light chain amyloidosis at an intravenous...
-
Expanding anti-CD38 immunotherapy for lymphoid malignancies
BackgroundLymphoid neoplasms, including multiple myeloma (MM), non-Hodgkin lymphoma (NHL), and NK/T cell neoplasms, are a major cause of blood cancer...
-
A Brief Report on Pre-Transfusion Testing in Patients Receiving the Anti-CD38 Monoclonal Antibody for Hematological Disorders in India
The aim of this study is to analyze the profile of patients receiving daratumumab and their presentation to the transfusion laboratory by looking at...
-
Development of ISB 1442, a CD38 and CD47 bispecific biparatopic antibody innate cell modulator for the treatment of multiple myeloma
Antibody engineering can tailor the design and activities of therapeutic antibodies for better efficiency or other advantageous clinical properties....
-
Case Study #3: Antibody Fragments in Radiopharmaceutical Therapy
Antibodies are widely used as versatile biological tools in cancer therapeutics. In radiopharmaceutical therapy, they have been extensively exploited...
-
Anti-CD38 targeted nanotrojan horses stimulated by acoustic waves as therapeutic nanotools selectively against Burkitt’s lymphoma cells
The horizon of nanomedicine research is moving toward the design of therapeutic tools able to be completely safe per se, and simultaneously be...
-
Steroid Premedication and Monoclonal Antibody Therapy: Should We Reconsider?
Monoclonal antibody (mAb) therapy is now considered a main component of cancer therapy in Australia. Although traditionally thought of as pure...
-
Antibody-drug conjugates in cancer therapy: innovations, challenges, and future directions
The emergence of antibody-drug conjugates (ADCs) as a potential therapeutic avenue in cancer treatment has garnered significant attention. By...
-
Update on the Application of Monoclonal Antibody Therapy in Primary Membranous Nephropathy
When first introduced, rituximab (RTX), a chimeric anti-CD20 monoclonal antibody, brought about an alternative therapeutic paradigm for primary...
-
Anti-cytomegalovirus antibody levels stratify human immune profiles across the lifespan
Human cytomegalovirus (hCMV) is a ubiquitous latent persistent herpesvirus infecting 60–90% of the population worldwide. hCMV carriage in...
-
Advances in antibody-based therapy in oncology
Monoclonal antibodies are a growing class of targeted cancer therapeutics, characterized by exquisite specificity, long serum half-life, high...
-
Monitoring, prophylaxis, and treatment of infections in patients with MM receiving bispecific antibody therapy: consensus recommendations from an expert panel
Bispecific antibodies (BsAbs) are emerging as an important novel class of immunotherapeutic agents for the treatment of multiple myeloma (MM), and...
-
Adverse events of antibody–drug conjugates on the ocular surface in cancer therapy
Antibody–drug conjugates consist of a monoclonal antibody attached to a cytotoxic therapeutic molecule by a connector. This association allows a...
-
CD38 identifies pre-activated CD8+ T cells which can be reinvigorated by anti-PD-1 blockade in human lung cancer
BackgroundCD38 has been observed expressing in activated T cells, while the features and functions of CD38+ T cells in human NSCLC are still unclear.
...
-
Emerging Trends in Monoclonal Antibody Therapies Targeting Cancer
Monoclonal antibody-based immunotherapy is a crucial component of cancer therapy. Advances in genetic engineering allowed for modifications that have...
-
Three
The chapter consists of three separate cases with the common theme of interference of certain drugs with pretransfusion laboratory tests, leading to...